{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:42:31Z","timestamp":1759405351239,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.020","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:02:39Z","timestamp":1673582559000},"page":"1354-1361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac\u00ae) among population aged 3\u00a0years and older in a large-scale use: A multi-center open-label study in China"],"prefix":"10.1016","volume":"41","author":[{"given":"Haitao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6364-6226","authenticated-orcid":false,"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeqing","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaodan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-2296","authenticated-orcid":false,"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4942-0068","authenticated-orcid":false,"given":"Yongjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.020_b0005","unstructured":"Coronavirus (who.int) https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_1."},{"key":"10.1016\/j.vaccine.2023.01.020_b0010","unstructured":"Weekly epidemiological update on COVID-19 \u2013 15 June 2022 (who.int) https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---15-june-2022."},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.020_b0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.020_b0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40249-021-00878-5","article-title":"Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.vaccine.2023.01.020_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.27940","article-title":"Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials","author":"Tian","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.01.020_b0030","unstructured":"Connolly CM, Ruddy JA, Boyarsky BJ, et al. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021. 10. 1136\/ annrh eumdis- 2021- 220231."},{"key":"10.1016\/j.vaccine.2023.01.020_b0035","doi-asserted-by":"crossref","unstructured":"Goshen-Lago T, Waldhorn I, Holland R, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021. 10. 1001\/ jamao ncol. 2021. 2675.","DOI":"10.1001\/jamaoncol.2021.2675"},{"key":"10.1016\/j.vaccine.2023.01.020_b0040","doi-asserted-by":"crossref","unstructured":"Ou MT, Boyarsky BJ, Motter JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021. 10. 1097\/ tp. 00000 00000 003780.","DOI":"10.1097\/TP.0000000000003780"},{"key":"10.1016\/j.vaccine.2023.01.020_b0045","doi-asserted-by":"crossref","unstructured":"Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated by BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021. 10. 1002\/ uog. 23729.","DOI":"10.1002\/uog.23729"},{"key":"10.1016\/j.vaccine.2023.01.020_b0050","unstructured":"Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273\u201382. 10. 1056\/ NEJMo a2104 983."},{"key":"10.1016\/j.vaccine.2023.01.020_b0055","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181-192. 10.1016\/S1473-3099(20)30843-4. Epub 2020 Nov 17. PMID: 33217362; PMCID: PMC7832443.","DOI":"10.1016\/S1473-3099(20)30843-4"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.020_b0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.020_b0065","doi-asserted-by":"crossref","unstructured":"Jara A, Undurraga EA, Gonz\u00e1lez C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021 Sep 2;385(10):875-884. 10.1056\/NEJMoa2107715. Epub 2021 Jul 7. PMID: 34233097; PMCID: PMC8279092.","DOI":"10.1056\/NEJMoa2107715"},{"key":"10.1016\/j.vaccine.2023.01.020_b0070","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-222. 10.1016\/S0140-6736(21)01429-X. Epub 2021 Jul 8. Erratum in: Lancet. 2022 Jan 29;399(10323):436. PMID: 34246358; PMCID: PMC8266301."},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.020_b0075","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.020_b0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.020_b0085","first-page":"977","article-title":"Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use. Chin","volume":"42","author":"Yang","year":"2021","journal-title":"J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.020_b0090","first-page":"385","article-title":"Safety analysis of domestic EV71 inactivated vaccine inoculated in large population after marketing[J]","volume":"35","author":"Zhang","year":"2019","journal-title":"Chin J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.020_b0095","first-page":"16","article-title":"Safety analysis of inactivated enterovirus 71 vaccine (Vero cells) [J]","volume":"30","author":"Wang","year":"2019","journal-title":"Chin J Public Health"},{"key":"10.1016\/j.vaccine.2023.01.020_b0100","unstructured":"Chen LP, Sun XY, Wei JJ, et al. Active and passive monitoring of safety of inactivated enterovirus 71 vaccine after marketing[J]. J Wenzhou Med Univ, 2020, 50(2): 149-153. DOI:CNKI:SUN:WZYX.0.2020-02-013. [article in Chinese]."},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.020_b0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/vaccines10030421","article-title":"Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis","volume":"10","author":"Gao","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.020_b0110","article-title":"The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"6","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.020_b0115","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1093\/cid\/ciab823","article-title":"Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile","volume":"75","author":"Bueno","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.020_b0120","doi-asserted-by":"crossref","unstructured":"Li C, Li A, Bi H, et al. Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study. medRxiv 2022.04.28.22274402; 10.1101\/2022.04.28.22274402.","DOI":"10.1101\/2022.04.28.22274402"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:10Z","timestamp":1759404190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000312"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac\u00ae) among population aged 3\u00a0years and older in a large-scale use: A multi-center open-label study in China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}